Detalle Publicación

ARTÍCULO
Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: Results of the CNIO-BR002 phase I-trial
Autores: Quintela-Fandino, Miguel; Bueno, Maria J.; Lombardia, Luis; Gil, Marta; Gonzalez-Martin, Antonio; Marquez, Raul; Bratos, Raquel; Guerra, Juan; Tan, Eugene; Lopez, Antonio; Colomer, Ramon; Salazar, Ramon; González Martín, Antonio
Título de la revista: MOLECULAR ONCOLOGY
ISSN: 1878-0261
Volumen: 8
Número: 8
Páginas: 1719-1728
Fecha de publicación: 2014
Resumen:
Level 1B was the RP2D as it provided adequate pharmacodynamic exposure to dovitinib. The G2071A germline variant act as a genetic modifier that renders different tumors sensitive to dovitinib.